U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H29O4.K
Molecular Weight 396.5616
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CANRENOATE POTASSIUM

SMILES

[K+].[H][C@@]12CC[C@@](O)(CCC([O-])=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])C=CC4=CC(=O)CC[C@]34C

InChI

InChIKey=JTZQCHFUGHIPDF-RYVBEKKQSA-M
InChI=1S/C22H30O4.K/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25;/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25);/q;+1/p-1/t16-,17+,18+,20+,21+,22-;/m1./s1

HIDE SMILES / InChI
Molecular Formula K
Molecular Weight 39.0983
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C22H29O4
Molecular Weight 357.4633
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/25389106

Potassium canrenoate (INN, JAN) or canrenoate potassium (USAN) (brand names Venactone, Soldactone), the potassium salt of canrenoic acid, is an aldosterone antagonist of the spirolactone group. Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body. Potassium canrenoate is not licensed in the UK, but may sometimes be prescribed off-licence to treat oedema. It is given intravenously. Potassium canrenoate is a mineralocorticoid receptor (MR) antagonist. The blockade with MR antagonist have beneficial effects in patients with heart failure and myocardial infarction, often attributed to blocking aldosterone action in the myocardium.

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Phase III
656
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Prevention and abolition of ouabain-induced ventricular tachycardia by potassium canrenoate in dogs.
1972 Aug
The influence of aldosterone and anticonvulsant drugs on electroencephalographic and clinical disturbances induced by the spirolactone derivative, potassium canrenoate.
1975 Jan
Ouabain-inhibiting activity of aldosterone antagonists.
1995 Jan
DNA damage in tissues of rat treated with potassium canrenoate.
2002 Feb 28
Endogenous and exogenous digoxin-like immunoreactive substances: impact on therapeutic drug monitoring of digoxin.
2002 Jul
A new turbidometric digoxin immunoassay on the ADVIA 1650 analyzer is free from interference by spironolactone, potassium canrenoate, and their common metabolite canrenone.
2003 Aug
Prenatal morphine exposure suppresses mineralocorticoid receptor-dependent basal synaptic transmission and synaptic plasticity in the lateral perforant path in adult male rats.
2003 Oct 15
The renin-angiotensin-aldosterone system in patients with depression compared to controls--a sleep endocrine study.
2003 Oct 29
Mineralocorticoid action and sodium-hydrogen exchange: studies in experimental cardiac fibrosis.
2003 Sep
Acute aldosterone antagonism improves cardiac vagal control in humans.
2004 Apr 7
Comparative evaluation of digoxin concentrations determined by three assay systems: TDx, IMx and OPUS.
2004 Jan
Low endogenous glucocorticoid allows induction of kidney cortical cyclooxygenase-2 during postnatal rat development.
2004 Jan
Effects of pH and the presence of micelles on the resolution of diuretics by reversed-phase liquid chromatography.
2004 Jan 2
Potassium canrenoate, an aldosterone receptor antagonist, reduces isoprenaline-induced cardiac fibrosis in the rat.
2004 Jun
Effects of the aldosterone receptor antagonist potassium canrenoate on renal blood flow and urinary output during prolonged increased intraabdominal pressure (IAP) in pigs.
2004 Oct
Screening procedure for detection of diuretics and uricosurics and/or their metabolites in human urine using gas chromatography-mass spectrometry after extractive methylation.
2005 Aug
A direct effect of aldosterone on endothelin-1 gene expression in vivo.
2007 Apr
Time-course reduction of renal function in rats on high sodium intake: acute reversal by potassium canrenoate.
2008 Apr
Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
2008 Dec
Corticosteroids mediate fast feedback of the rat hypothalamic-pituitary-adrenal axis via the mineralocorticoid receptor.
2008 Jun
Graz Endocrine Causes of Hypertension (GECOH) study: a diagnostic accuracy study of aldosterone to active renin ratio in screening for primary aldosteronism.
2009 Apr 7
Pharmacological characterization of intracellular, membrane, and plasma binding sites for corticosterone in house sparrows.
2009 Sep 1
Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.
2010
Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites.
2010 Jul
Amiloride reduces portal hypertension in rat liver cirrhosis.
2010 Jun
Heterogeneous nuclear ribonucleoprotein A2/B1 is a tissue-specific aldosterone target gene with prominent induction in the rat distal colon.
2013 Jan 15
Patents

Patents

US2011257140
3
US2014322323
3

Sample Use Guides

In Vivo Use Guide
400 mg of Potassium-Canrenoate
Route of Administration: Intravenous
In Vitro Use Guide
potassium canrenoate, in a concentration-dependent manner (3-30 uM), inhibited the increase in basal tone induced by receptorial (ouabain), most likely acting as antagonist for ouabain binding site on Na(+)-K+ATPase pump
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:48:38 GMT 2023
Edited
by admin
on Fri Dec 15 18:48:38 GMT 2023
Record UNII
M671F9NLEA
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CANRENOATE POTASSIUM
USAN  
USAN  
Official Name English
CANRENONE FREE ACID POTASSIUM SALT [MI]
Common Name English
NSC-757789
Code English
CANRENOATE POTASSIUM [USAN]
Common Name English
KANRENOL
Brand Name English
POTASSIUM CANRENOATE [MART.]
Common Name English
POTASSIUM CANRENOATE [JAN]
Common Name English
POTASSIUM CANRENOATE
INN   MART.   WHO-DD  
INN  
Official Name English
SOLDACTONE
Brand Name English
PREGNA-4,6-DIENE-21-CARBOXYLIC ACID, 17-HYDROXY-3-OXO-, MONOPOTASSIUM SALT (17.ALPHA.)-
Common Name English
CANRENONE FREE ACID POTASSIUM SALT
MI  
Common Name English
potassium canrenoate [INN]
Common Name English
Potassium 17-hydroxy-3-oxo-17α-pregna-4,6-diene-21-carboxylate
Common Name English
Potassium canrenoate [WHO-DD]
Common Name English
SC-14266
Code English
Classification Tree Code System Code
NCI_THESAURUS C547
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
WHO-VATC QC03DA02
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
WHO-ATC C03DA02
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
Code System Code Type Description
RXCUI
1981
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY RxNorm
ChEMBL
CHEMBL1616951
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
DRUG BANK
DB09015
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
NCI_THESAURUS
C81161
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
FDA UNII
M671F9NLEA
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
INN
2448
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
ECHA (EC/EINECS)
218-554-9
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
NSC
757789
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
MESH
D002191
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
EPA CompTox
DTXSID2045602
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
PUBCHEM
23671691
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
WIKIPEDIA
POTASSIUM CANRENOATE
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
DRUG CENTRAL
477
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
SMS_ID
100000091863
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
CAS
2181-04-6
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
MERCK INDEX
m3023
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY Merck Index
EVMPD
SUB09983MIG
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
Related Record Type Details
Structure of CANRENOIC ACID
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of CANRENOIC ACID
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966